Today's News |
Vancouver-based Bold Therapeutics BOLD-100 Program to receive up to $289,032.00 from National Research Council of Canada for Development Support
Wednesday, December 23, 2020Company Profile | Follow Company
Vancouver, BC, December 21, 2020--(T-Net)--Bold Therapeutics' announced that its BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support.
Bold Therapeutics (Vancouver, BC) will receive up to $289,032.00 for a project to prepare preclinical efficacy data in live SARS-CoV-2 (COVID-19), support preparation for clinical trials, and to support manufacturing of its BOLD-100 investigational therapy to treat patients with viral infections, including COVID-19.
The company says it is currently completing an in vivo antiviral safety and efficacy study and hope to be in the clinic in mid-2021. Meanwhile, their second clinical study of first-in-class BOLD-100 in combination with FOLFOX in the treatment of advanced GI cancers continues to actively enroll patients at six cancer hospitals across Canada.
For more information and to read the National Research Council's press release, please visit:
https://www.canada.ca/en/national-research-council/news/2020/12/national-research-council-of-canada-supports-development-of-4-covid-19-therapeutic-candidates.html
About Bold Therapeutics
Bold Therapeutics was founded in 2018 by a team of biopharma industry veterans to develop and commercialize BOLD-100, a first-in-class anti-resistance therapeutic.
BOLD-100, a ruthenium-based small molecule therapeutic, appears to significantly enhance the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway.
Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
Other Recent Company News |
|||||||||||||||||||
|